Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR6390 Combined With Pyrotinib in HER2+ Advanced Gastric Cancer
NCT03480256Phase 1Unknown
- Sponsor
- Peking University
- Start
- Jul 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dalpiciclib in gastric cancer (GC), sponsored by Peking University. Primary endpoint: Maximum Tolerated Dose at 42 days. Status: unknown.
02
Drugs
dalpiciclib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03480256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03480256.